Page last updated: 2024-09-04

glucagon and canagliflozin

glucagon has been researched along with canagliflozin in 8 studies

Compound Research Comparison

Studies
(glucagon)
Trials
(glucagon)
Recent Studies (post-2010)
(glucagon)
Studies
(canagliflozin)
Trials
(canagliflozin)
Recent Studies (post-2010) (canagliflozin)
26,0391,4983,054998194975

Protein Interaction Comparison

ProteinTaxonomyglucagon (IC50)canagliflozin (IC50)
Sodium/glucose cotransporter 1Homo sapiens (human)0.9497
Sodium/glucose cotransporter 2Homo sapiens (human)0.0039

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K1
Hara, K; Inukai, T; Naruse, R; Suetsugu, M; Takebayashi, K; Terasawa, T; Tsuchiya, T1
Carria, LR; Cengiz, E; Patel, NS; Sherr, JL; Tamborlane, WV; Van Name, MA; Weinzimer, SA1
Eckel, RH; Koh, KK; Lim, S1
Kondo, Y; Mitsumatsu, T; Okahata, S; Sakamoto, K; Shiba, T; Tanaka, S1
Kakizaki, S; Kikuchi, O; Kitamura, T; Kobayashi, M; Kohno, D; Matsui, S; Sasaki, T; Suga, T; Takeuchi, K; Wada, E; Yamada, M; Yokota-Hashimoto, H1
Bojsen-Møller, KN; Dirksen, C; Fenger, M; Holst, JJ; Kristiansen, VB; Madsbad, S; Martinussen, C; Svane, MS; van Hall, G; Veedfald, S; Wewer Albrechtsen, NJ1
Fushimi, Y; Hirukawa, H; Horiya, M; Iwamoto, Y; Kaku, K; Kan, Y; Kaneto, H; Kinoshita, T; Kohara, K; Mashiko, A; Mizoguchi-Tomita, A; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Okauchi, S; Sanada, J; Shimoda, M; Tatsumi, F1

Reviews

1 review(s) available for glucagon and canagliflozin

ArticleYear
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
    Atherosclerosis, 2018, Volume: 272

    Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018

Trials

3 trial(s) available for glucagon and canagliflozin

ArticleYear
Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.
    Endocrine journal, 2017, Sep-30, Volume: 64, Issue:9

    Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome

2017
Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:2

    Topics: Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazoles; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines

2019
The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    American journal of physiology. Endocrinology and metabolism, 2020, 06-01, Volume: 318, Issue:6

    Topics: Blood Glucose; C-Peptide; Canagliflozin; Cross-Over Studies; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Middle Aged; Pancreatic Polypeptide; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2020

Other Studies

4 other study(ies) available for glucagon and canagliflozin

ArticleYear
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
    American journal of physiology. Endocrinology and metabolism, 2014, Jun-01, Volume: 306, Issue:11

    Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2014
Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.
    Diabetes technology & therapeutics, 2017, Volume: 19, Issue:11

    Topics: Adolescent; Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Young Adult

2017
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Molecular metabolism, 2019, Volume: 19

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2019
Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
    Journal of diabetes research, 2020, Volume: 2020

    Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Treatment Outcome

2020